The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what FDA Peptide Reclassification 2026: What It Means for Providers FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea FDA considers adding a dozen peptides to its bulk drug compounding list RAPS